Pyridazinone and pyridone compounds

A pyridazinone or pyridone compound of general formula (I′), or pharmaceutically acceptable salt, hydrate, or solvate thereof,

• wherein
• X is CH;
• R1 is phenyl, optionally substituted with R11,
• wherein R11 is selected from the group consisting of halogen, halo-C1-3-alkyl, and C1-6-alkoxy;
• R2 is H or triazolyl;
• (i) X3 is O or S, and
• R3 is selected from the group consisting of H, C1-6-alkyl, C2-6-alkenyl, and phenyl, said phenyl being optionally substituted one or more times with R31, each R31 is independently selected from the group consisting of halogen, halo-C1-3-alkyl and C1-6-alkoxy;
• or
• (ii) X3 is NR3′, and
• R3 and R3′ together with the nitrogen, to which they are attached, form a 5 or 6 membered saturated heterocyclic ring, —N3, or triazole, said triazole being optionally substituted with R32, wherein R32 is selected from the group consisting of phenyl, C1-6-alkyl, and —CO2(C1-3-alkyl);
• or
• R3′ is H or C1-3-alkyl, and
• R3 is selected from the group consisting of H;
• C1-6-alkyl;
• C2-6-alkenyl;
• C2-6-alkynyl;
• C3-6-cycloalkyl-C1-6-alkyl;
• C1-6-cycloalkyl;
• cyano-C1-6-alkyl;
• amino-C1-6-alkyl;
• benzyl;
• pyridyl;
• saturated 5 or 6 membered heterocyclic ring having 1 to 2 heteroatoms selected from N, O, and S, and wherein said N is optionally substituted with C1-6-alkyl;
• R33R33′N—C1-6-alkylenyl;
• and phenyl, said phenyl being optionally substituted 1 to 3 times with R34;
• wherein
• R33 and R33′ are both C1-3-alkyl, or R33 and R33′ together with the nitrogen, to which they are attached, form a saturated 5 or 6 membered heterocyclic ring optionally comprising one further heteroatom selected from N, O, and S;
• each R34 is independently selected from the group consisting of NR35R35′, hydroxy and C1-6-alkoxy;
• or two adjacent R34 together with the carbon atoms, to which they are attached, form a 5 or 6 membered fused heterocyclic ring comprising 1 or 2 heteroatom(s) each independently selected from N, O and S;
• wherein R35 and R35′ are both H or C1-6-alkyl;
• or R35 and R35′ together with the nitrogen, to which they are attached, form a 5 or 6 membered saturated heterocyclic ring optionally further comprising as a ring member O, S, N, or NR36, wherein R36 is H, C1-6-alkyl or benzoyl;
• R4 is selected from the group consisting of —CN;
• —C(═O)X4R41;
• phenyl, wherein said phenyl is optionally substituted with R42;
• and an 5 or 6 membered unsaturated heterocyclic ring having 1 to 4 heteroatoms each independently selected from N, O and S and being optionally substituted one or more times with R43;
• wherein
• X4 is O, S, or NH;
• and
• R41 is selected from the group consisting of H, C1-6-alkyl, R44R44′N—C1-6-alkylenyl, and —NHR45,
• wherein R44 and R44′ are both H or C1-6-alkyl;
• or R44 and R44′ together with the nitrogen, to which they are attached, form a 5 or 6 membered saturated heterocyclic ring;
• and
• R45 is H or imino-C1-6-alkyl;
• or
• X4 and R41 taken together form —N═CR46R47, wherein
• R46 is H or methyl, and
• R47 is di(C1-3-alkyl)amino;
• R42 is selected from the group consisting of halogen, halo-C1-3-alkyl, and C1-6-alkoxy;
• each R43 is independently selected from the group consisting of —OH, —SH, and methyl.